SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: biodoc who wrote (242)5/31/1998 6:08:00 PM
From: Dennis  Respond to of 645
 
Biodoc, totally agree with you. How about a merger????? :o)

Seriously, there is a target of 38 from Avir. Don't you think this is extremely LOW considering the potential market. I mean look a Viagra?? Very small market compared to Avir. Granted ,however ,that you would only need to take Avir ONCE per year. And ,if your lucky, Viagra ONCE per day!!!

Seriously again, people don't die from impotence. The cost is MUCH higher for those who catch the flu.

Common sense. But then again, we are talking $$$$$ so common sense doesn't usually apply. Unfortunately hype usually wins.



To: biodoc who wrote (242)6/1/1998 9:29:00 AM
From: SJS  Respond to of 645
 
Very helpful. I went back to the press release, and I didn't pick up the subtlety of this comment the first time:

RelenzaTM, the first effective treatment for all strains of influenza, was filed with the Therapeutic Goods Administration for marketing approval in Australia on 30 March 1998,after Phase III clinical trials were conducted in the Southern Hemisphere during the last flu season.

Appreciate the explanation.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News